icon-folder.gif   Conference Reports for NATAP  
 
  HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis
December 8-12, 2013
Big Island, Hawaii
Back grey_arrow_rt.gif
 
 
 
Simeprevir Overview: From IFN-Containing to IFN-Free Regimens
 
 
  Reported by Jules Levin
HEP DART 2013, December 8-12, 2013, Big Island, HI, USA
 
AASLD: SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-na´ve and prior null responder patients: The COSMOS study - (11/05/13)
 
An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated - (12/16/13)
 
AASLD: Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/02/13)
 
AASLD: Janssen at AASLD - (11/18/13)
 
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013
 
Simeprevir (Olysio) J & J Patient Access Programs
 
Sofosbuvir (Sovaldi) - Gilead U.S. Patient Assistance Program
 
Gaston Picchio
Janssen Research & Development LLC,
Titusville, NJ, USA
 
Simeprevir+Sofosbuvir COSMOS Results below

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif

AASLD15.gif

AASLD16.gif

AASLD17.gif

AASLD18.gif

AASLD19.gif

AASLD20.gif

AASLD21.gif

AASLD22.gif

AASLD23.gif